EUCTR2011-003130-14-IT进行中（未招募）不适用
A placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients” - CSUC-01/10
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female = 18 years of age. 2. Well established diagnosis of moderate to moderately severe chronic active UC with a CAI score =9, an endoscopic score =2, not responding adequately to currently available therapies and potential candidates for colectomy. Previously tried therapies should include: • At least one treatment course with mesalazine; at least 2.4 g/day for at least 4 weeks, or at least one treatment course with similar drugs in this class. • At least one treatment course of corticosteroids; at least 0.75 mg/kg as starting dose. • At least one treatment course of azathioprine or mercaptopurine of at least 3 months duration and/or at least one adequate treatment course of an anti-TNF alpha. • Any unsuccessful combination treatment of the above. • May have tried treatment with cyclosporine and/or tacrolimus or any otherimmunosuppressant/immunomodulating agent. • Intolerance to any of the above medications is judged as inadequate response. 3. Patients shall at study enrolment be on an accumulated stable tolerable GCS dose equivalent to at least 140 mg of prednisolone/prednisone (by any route of administration) for the last two weeks. Patients may also be on concomitant therapies such as, but not restricted to, 5-ASA, azathioprine and sulphasalazine. 4. Ability to understand the treatment, willingness to comply with all study requirements, and ability to provide informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Patients with suspicion of Crohn’s enterocolitis, ischaemic colitis, radiation colitis, diverticular disease associated colitis, as well as microscopic colitis should be excluded. Patients with disease limited to the rectum (ulcerative proctitis) should also be excluded. 2. History or presence of a clinically significant cardiovascular, hepatic, renal, haematological, endocrine, neurological, psychiatric disease, or immune compromised state as judged relevant by the investigator. 3. Patients with acute fulminant UC and/or signs of systemic toxicity to an extent that requires immediate surgical action. 4. History or presence of any colonic malignancy and/or dysplasia. 5. Concomitant treatment with cyclosporine, tacrolimus, anti-TNFs or similar immunosuppressants/immunomodulators is not allowed and should have been discontinued 4 weeks before enrolment. Patients who fail the wash-out criteria can undergo wash-out and be re-screened at a later time point. 6. Treatment with antibiotics or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within two weeks before enrolment. 7. An active ongoing infection 8. Positive Clostridium difficile stool assay. 9. Currently receiving parenteral nutrition or blood transfusions. 10. Pregnancy or breast-feeding. 11. Women of childbearing potential not using reliable contraceptive methods (reliable methods are barrier protection, hormonal contraception, intra-uterine device or abstinence). 12. Concurrent participation in another clinical study with investigational therapy or previous use of investigational therapy within 30 days before enrolment. Patients who fail the wash-out criteria can undergo wash-out and be re-screened at a later time point.
研究者
相似试验
进行中（未招募）
不适用
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.Treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-DETakeda Europe R &D Centre Ltd400
进行中（未招募）
不适用
A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentChronic active treatment refractory ulcerative colitisMedDRA version: 16.1Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-003130-14-HUInDex Pharmaceuticals AB120
进行中（未招募）
不适用
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.EUCTR2005-002316-24-EETakeda Europe R &D Centre Ltd400
进行中（未招募）
不适用
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-LVTakeda Europe R &D Centre Ltd400
进行中（未招募）
1 期
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-DKTakeda Europe R &D Centre Ltd400